John Pinching is an Editor for PharmaTimes Media Ltd, specializing in pharmaceutical and healthcare news. With a focus on the latest developments in the industry, John covers topics such as drug approvals, partnerships, mergers, and breakthrough treatments. His articles provide valuable insights into the ever-evolving world of healthcare and its impact on patients and professionals alike.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
This information evolves through machine learning and human feedback. Improve this profile .
Tezspire is a drug for severe asthma and Forxiga is used to treat chronic heart failure
The purchased therapies concerned are Cardioxane, Totect, Ethyol and Savene
The collaboration will focus on multiple enzyme cargoes modified using Aliada's modular delivery platform
The new vaccine is an alternative to injected versions and no medical training is needed to deliver it
The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study
The therapy involves long-term enzyme replacement therapy for aduls with Fabry disease
The amalgamated company will focus on advancing neflamapimod for the treatment of dementia
By: John Pinching
Aquablation is a robotic method that uses a high-pressure saline solution to remove tissue
By: John Pinching
Mitazalimab is a monoclonal antibody that has been created to sensitize tumours to chemotherapy
By: John Pinching
The treatment is indicated for adults with moderate-to-severe chronic hand eczema
(833) 317-6278 
